Sidney A Scudder

Title(s)Professor, MED: Int Med Hematology/Oncology
SchoolSchool of Medicine
AddressCancer Ctr So, #3016
CA 95817
Phone916-475-9349
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes. PLoS One. 2024; 19(4):e0295987. May T, Clement MS, Halait H, Kohlmann A, Kohlmann M, Lai J, Lee N, Li-Sucholeiki X, Meldgaard P, Joshi S, Scudder S, Shrestha N, Sorensen B, Kiral M, O'Donnell P. PMID: 38593164; PMCID: PMC11003689.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer. PLoS One. 2022; 17(4):e0267362. Ho HL, Jiang Y, Chiang CL, Karwowska S, Yerram R, Sharma K, Scudder S, Chiu CH, Tsai CM, Palma JF, Sharma A, Chou TY. PMID: 35482671; PMCID: PMC9049536.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    3. Performance Characteristics of a Real-Time Polymerase Chain Reaction Assay for the Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Plasma Samples of Non-Small Cell Lung Cancer (NSCLC) Patients. Mol Diagn Ther. 2020 08; 24(4):451-460. O'Donnell P, May T, DeMartin K, Ferguson J, Halait H, Wei W, Yu K, Scudder S. PMID: 32406048.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    4. Budget Impact Analysis of EGFR Mutation Liquid Biopsy for First- and Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer in Greece. Diagnostics (Basel). 2020 Jun 24; 10(6). Cheng M, Akalestos A, Scudder S. PMID: 32599934; PMCID: PMC7345049.
      View in: PubMed   Mentions: 5  
    5. Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer. 2018 12; 126:1-8. Wu YL, Lee V, Liam CK, Lu S, Park K, Srimuninnimit V, Wang J, Zhou C, Appius A, Button P, Hooper G, Palma JF, Schulze K, Scudder S, Shames DS, Yin AY, Zhang G, Mok T, ENSURE FASTACT-2 and ASPIRATION Investigators. PMID: 30527172.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    6. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. J Mol Diagn. 2018 07; 20(4):483-494. Keppens C, Palma JF, Das PM, Scudder S, Wen W, Normanno N, van Krieken JH, Sacco A, Fenizia F, Gonzalez de Castro D, Hönigschnabl S, Kern I, Lopez-Rios F, Lozano MD, Marchetti A, Halfon P, Schuuring E, Setinek U, Sorensen B, Taniere P, Tiemann M, Vosmikova H, Dequeker EMC. PMID: 29704571.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    7. The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer. J Pers Med. 2017 Jun 28; 7(3). Cheng MM, Palma JF, Scudder S, Poulios N, Liesenfeld O. PMID: 28657610; PMCID: PMC5618152.
      View in: PubMed   Mentions: 6  
    8. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecol Oncol. 2014 Oct; 135(1):25-33. Vergote I, Schilder RJ, Pippitt CH, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM. PMID: 25019569.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    9. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol. 2009 Jul; 4(7):862-8. Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara PN, Perkins N, Gandara DR. PMID: 19494788.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    10. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008 Nov 15; 14(22):7554-63. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz HJ. PMID: 19010874; PMCID: PMC2586993.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    11. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008 Jan 01; 26(1):76-82. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. PMID: 18165643.
      View in: PubMed   Mentions: 191     Fields:    Translation:HumansCTClinical Trials
    12. Primary clear cell adenocarcinoma of the rectovaginal septum treated with concurrent chemoradiation therapy: a case report. Int J Gynecol Cancer. 2008 Sep-Oct; 18(5):1118-21. Guiou M, Hall WH, Konia T, Scudder S, Leiserowitz G, Ryu JK. PMID: 17986241.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    13. Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. Int J Gynecol Cancer. 2007 Mar-Apr; 17(2):373-8. Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. PMID: 17362315.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    14. Long-term results of maximally aggressive trimodality therapy in a high-risk subset of early-stage cervical cancer patients. J Reprod Med. 2006 May; 51(5):383-8. Elliott KS, Borowsky ME, Malka ES, Scudder SA, Leiserowitz GS, Russell AH. PMID: 16779984.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoeitin. Gynecol Oncol. 2006 Jul; 102(1):98-102. Lin A, Ryu J, Harvey D, Sieracki B, Scudder S, Wun T. PMID: 16406065.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    16. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer. 2006 Jan-Feb; 16(1):298-305. Smith HO, Jiang CS, Weiss GR, Hallum AV, Liu PY, Robinson WR, Cheng PC, Scudder SA, Markman M, Alberts DS. PMID: 16445649.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    17. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol. 2005 Mar; 96(3):610-5. Scudder SA, Liu PY, Wilczynski SP, Smith HO, Jiang C, Hallum AV, Smith GB, Hannigan EV, Markman M, Alberts DS, Southwest Oncology Group. PMID: 15721401.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    18. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. PMID: 15530258.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    19. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecol Oncol. 2004 Jul; 94(1):98-106. Stiff PJ, Shpall EJ, Liu PY, Wilczynski SP, Callander NS, Scudder SA, Jazieh AR, Samlowski W, McCoy J, Alberts DS, Southwest Oncology Group Study. PMID: 15262126.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    20. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. Cancer Chemother Pharmacol. 2004 Oct; 54(4):283-9. Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. PMID: 15184995.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    21. Chemoradiation for primary invasive squamous carcinoma of the vagina. Int J Gynecol Cancer. 2004 Jan-Feb; 14(1):110-7. Dalrymple JL, Russell AH, Lee SW, Scudder SA, Leiserowitz GS, Kinney WK, Smith LH. PMID: 14764038.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    22. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 2003 Oct 01; 98(7):1514-20. Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK. PMID: 14508840.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    23. Endometriosis-related malignancies. Int J Gynecol Cancer. 2003 Jul-Aug; 13(4):466-71. Leiserowitz GS, Gumbs JL, Oi R, Dalrymple JL, Smith LH, Ryu J, Scudder S, Russell AH. PMID: 12911723.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    24. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. PMID: 11251003.
      View in: PubMed   Mentions: 249     Fields:    Translation:Humans
    25. Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21(WAF1/CIP1) predicts survival and good response to platinin-based chemotherapy. Hum Pathol. 1999 Jun; 30(6):640-7. Costa MJ, Hansen CL, Walls JE, Scudder SA. PMID: 10374771.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. 13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial. Gynecol Oncol. 1998 Dec; 71(3):386-90. Weiss GR, Liu PY, Alberts DS, Peng YM, Fisher E, Xu MJ, Scudder SA, Baker LH, Moore DF, Lippman SM. PMID: 9887236.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    27. Clinicopathologic significance of transitional cell carcinoma pattern in nonlocalized ovarian epithelial tumors (stages 2-4). Am J Clin Pathol. 1998 Feb; 109(2):173-80. Costa MJ, Hansen C, Dickerman A, Scudder SA. PMID: 9583889.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    28. Prophylactic chemoradiation of inguinofemoral lymph nodes in patients with locally extensive vulvar cancer. Gynecol Oncol. 1997 Sep; 66(3):509-14. Leiserowitz GS, Russell AH, Kinney WK, Smith LH, Taylor MH, Scudder SA. PMID: 9299268.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    29. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies. Anticancer Res. 1994 Sep-Oct; 14(5A):1703-9. Walker R, Crebbin V, Stern J, Scudder S, Schwartz P. PMID: 7847804.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva. Gynecol Oncol. 1992 Oct; 47(1):14-20. Russell AH, Mesic JB, Scudder SA, Rosenberg PJ, Smith LH, Kinney WK, Townsend DE, Trelford JD, Taylor MH, Zukowski CL, et al. PMID: 1427394.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    31. The integration of computed tomography and magnetic resonance imaging in treatment planning for gynecologic cancer. Clin Obstet Gynecol. 1992 Mar; 35(1):55-72. Russell AH, Anderson M, Walter J, Kinney W, Smith L, Scudder S. PMID: 1544250.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    32. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2. Clin Pharmacol Ther. 1991 Mar; 49(3):307-13. Meyers FJ, Paradise C, Scudder SA, Goodman G, Konrad M. PMID: 2007324.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCTClinical Trials
    33. Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study. J Immunother (1991). 1991 Feb; 10(1):57-62. Perez EA, Scudder SA, Meyers FA, Tanaka MS, Paradise C, Gandara DR. PMID: 2012799.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. DNA cross-linking and cytotoxicity of the alkylating cyanomorpholino derivative of doxorubicin in multidrug-resistant cells. J Natl Cancer Inst. 1988 Oct 19; 80(16):1294-8. Scudder SA, Brown JM, Sikic BI. PMID: 3172256.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    35. High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group. Semin Oncol. 1986 Dec; 13(4 Suppl 4):26-32. Sikic BI, Scudder SA, Ballon SC, Soriero OM, Christman JE, Suey L, Ehsan MN, Brandt AE, Evans TL. PMID: 3099393.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    Sidney's Networks
    Concepts (205)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (19)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California